GG & lao sai. Really Pity those follow the previous facebook live teachers & u all sangkut now.

GG & lao sai. Really Pity those follow the previous facebook live teachers & u all sangkut now.

GG & lao sai. Really Pity those follow the previous facebook live teachers & u all sangkut now.

MYEG – Healthcare Key Results Driver, New Projects on the Way - http://klse.i3investor.com/m/blog/kltrader/2021-09-02-story-h1570693762-MYEG_ndash_Healthcare_Key_Results_Driver_New_Projects_on_the_Way.jsp (Share from StockHunter)

MYEG – Healthcare Key Results Driver, New Projects on the Way - http://klse.i3investor.com/m/blog/kltrader/2021-09-02-story-h1570693762-MYEG_ndash_Healthcare_Key_Results_Driver_New_Projects_on_the_Way.jsp (Share from StockHunter)

wow wow

possible hihi

Third plant on the cards
Pentamaster will be spending RM60 million between FY2021 and FY2023 to develop its MDI manufacturing business at its 3.5-acre plant in Batu Kawan as well as setting up a new plant in the area.

“Once completed, we expect 70% of the capacity from our existing Batu Kawan plant to be occupied by the MDI business,” says Chuah.

Pentamaster is also applying to Penang Development Corp (PDC) to acquire 10 acres in Batu Kawan for future expansion projects. “We plan to build a 200,000 sq ft manufacturing facility there, which will be the third plant for the group, focusing on MDI, WAS and FAS,” he adds.

The group generated a net profit of RM70.88 million on revenue of RM418.77 million in FY2020. It reported its highest-ever quarterly revenue of RM130.64 million in the second quarter ended June 30, 2021 (2QFY2021), with a net profit of RM17.93 million. This brings its revenue and net profit for 1HFY2021 to RM245.81 million and RM34.01 million respectively.

“In the next three to five years, we target our revenue to achieve double-digit growth every year. By venturing into new businesses like MDI and WAS, Pentamaster could continue to grow besides relying on ATE and FAS,” says Chuah.

He notes that the operations of many medical device manufacturers remain labour-intensive. But Pentamaster’s advantage is that it is essentially an automation and equipment firm. In other words, when the company is making medical devices, its manufacturing processes can be highly automated.

Chuah says manufacturing of medical devices involves more precision parts moulding and mechanical assembly. So, for Pentamaster, making medical devices is not as big a challenge as making semiconductor equipment.

“However, MDI’s barriers to entry are high, to obtain all the approvals and certifications from healthcare authorities, as well as to maintain the consistency and quality compliance of our products. We need to make sure that our medical devices do not have any quality defects.”

In spite of the stringent requirements, Chuah says Pentamaster is confident of obtaining these approvals due to its experienced engineering team and automation approach to provide consistency in quality and compliance. “We can add value to our MDI products from quality throughput to cost with a highly automated manufacturing process. We design and build the equipment ourselves. We have a machine vision inspection system and test equipment to make sure all the medical devices manufactured are auto inspected and tested to ensure standards compliance,” he says.

He adds that pen needles and IVCs are just a start for Pentamaster’s MDI manufacturing business. Moving forward, the group intends to expand its product portfolio to include other products such as safety syringes, scalpel and suture kits, lancets, dialysis filters, scalp vein sets and blood collection tubes.

“We have seen higher demand for these single-use medical devices since the Covid-19 outbreak. Nowadays, people are less willing to go to hospitals, so we see more people buying pen needles for home use. Meanwhile, many hospitals are still full of Covid-19 patients, who would also need IVCs.

“With our advanced manufacturing technology, we aim to be one of the global players in the medical device manufacturing sector,” he says.

‘PIL is a steady stock while Pentamaster is a more exciting one’
Shares in Pentamaster had gained over 5% year to date (YTD) to close at RM5.42 last Wednesday, giving it a market capitalisation of RM3.86 billion. The counter is currently trading at a historical price-earnings ratio (PER) of 54.2 times.

In contrast, PIL’s share price has dropped close to 9% YTD to settle at HK$1.03, bringing its market value to HK$2.47 billion. The stock carries a PER of merely 10.2 times.

Comparing the share price performance of the two listed vehicles, Chuah acknowledges that the stock valuation of Hong Kong-listed PIL is lower. “Like it or not, we are still a small stock in the eyes of international investors. I guess Malaysian investors are more familiar with ATE companies like us. Essentially, PIL and Pentamaster are the same company. But from a stock investing perspective, I would say PIL is a steady stock while Pentamaster is a more exciting one,” he says.

Economic Recovery Plan
01 September 2021. Wednesday

FROM THE EDGE
Edge Weekly
Medical device business the next big thing for Pentamaster


September 01, 2021 18:00 pm +08

This article first appeared in The Edge Malaysia Weekly, on August 23, 2021 - August 29, 2021.
Chuah: We (ATE manufacturers) do not want to sell our products at lower prices just to compete with our competitors. We need to look into multiple avenues of growing our businesses ... If you think about it, most of us are not going into industries that we are totally unfamiliar with. (Photo by Pentamaster)
Chuah: We (ATE manufacturers) do not want to sell our products at lower prices just to compete with our competitors. We need to look into multiple avenues of growing our businesses ... If you think about it, most of us are not going into industries that we are totally unfamiliar with. (Photo by Pentamaster)


PENANG-based semiconductor equipment vendor and automation house Pentamaster Corp Bhd is the latest company to embark on the diversification route to increase its revenue streams and generate sustainable earnings growth.

While its peers ViTrox Corp Bhd and MI Technovation Bhd have gone into precision smart farming and semiconductor materials business respectively, Pentamaster is venturing into the medical device industry (MDI). The group is producing single-use medical devices such as dual-safety pen needles and safety intravenous catheter (IVC), which are mostly sold through distributor agents.

Pentamaster, together with Greatech Technology Bhd, ViTrox and MI Technovation, are known as the Big Four automated test equipment (ATE) manufacturers listed on Bursa Malaysia.

Advertisement

Pentamaster co-founder and chairman Chuah Choon Bin says the local ATE companies are diversifying into various sectors as they ascribe to the adage of “not putting all of one’s eggs into the same basket”.

“As technology gets more mature, the red ocean is coming in. China is up and coming in the semiconductor sector. The Chinese firms are executing their plans very fast. What you can do this year, China might be able to do it next year, and probably cheaper and better than you,” he tells The Edge in a telephone interview.

To remain ahead of the game, ATE manufacturers such as Pentamaster are thinking about the sustainability of their companies. “We do not want to sell our products at lower prices just to compete with our competitors. We need to look into multiple avenues of growing our businesses. We have to sustain our profitability and profit margins. If you think about it, most of us are not going into industries that we are totally unfamiliar with,” Chuah points out.

For instance, Pentamaster is going into the medical sector because it has the automation and equipment know-how, he says. As for the other local ATE firms, some of them are going into smart farming, battery or solar automation as they have their respective core technology to do so.

Chuah, 60, is the single largest shareholder of Pentamaster with a 19.73% stake. An electronics and electrical engineering graduate from University of Auckland, New Zealand, he previously served as an automation engineer for National Semiconductor and Intel Technology Malaysia.

Other prominent names among its top 30 shareholders include Kumpulan Wang Persaraan (Diperbadankan) (KWAP), the Employees Provident Fund (EPF), Permodalan Nasional Bhd (PNB), Lembaga Tabung Haji, AIA Bhd, Kenanga Growth Fund and two Vanguard funds.

Pentamaster has four major business segments, namely ATE, MDI, factory automation solutions (FAS) and warehouse automation systems (WAS). The group has two plants in Penang: one in Bayan Lepas, which also acts as its main office, and another in Batu Kawan.

Notably, 2021 marks Pentamaster’s 30th anniversary, the company’s 18th year of listing on Bursa Malaysia and also the third anniversary of 63%-owned Pentamaster International Ltd’s (PIL) listing on the Hong Kong Stock Exchange.

Pentamaster ventured into MDI before the Covid-19 outbreak and was thus ready when the pandemic broke out.

As for its FAS business segment, the company has further diversified its services by providing medical assembly and medical automation solutions to clients. Its ATE division, meanwhile, contributes about 70% to group revenue and the remaining 30% is derived from its FAS division.

Chuah, however, expects the MDI and WAS divisions to each contribute 5% to Pentamaster’s revenue in the financial years ending Dec 31, 2021 and 2022 (FY2021 and FY2022), while contribution from the FAS division is expected to increase to 35% and the ATE division to reduce to 55%.

“Among the four business segments, we are particularly excited about the growth story of our MDI division as we expect its contribution to increase further to 5% to 10% by FY2023,” he says.

Edge Weekly - Chuah: We (ATE manufacturers) do not want to sell our products at lower prices just to compete with our competitors. We need to look into multiple avenues of growing our businesses ... If you think about it, most of us are not going into industries that we are totally unfamiliar with. (Photo by Pentamaster) - http://www.theedgemarkets.com/article/medical-device-business-next-big-thing-pentamaster (Share from StockHunter)

tomorrow 1.10

had tambah 300 lots more today

发布于 2021年09月01日 15时46分 • 最后更新 2小时前 • 报导：雷洁敏
方案集团携手利直南　助政府加速新冠疫苗接种率

（吉隆坡1日讯）方案集团（SOLUTN，0093，创业板）和利直南（DKSH，5908，主板消费股）携手合作，协助政府加速新冠肺炎疫苗接种率，尽快把疫苗配送到卫生部营运的各个接种中心，并确保以安全可靠的方式处理疫苗。

方案集团周三发文告指出，利直南已被卫生部指定为处理中国康希诺公司（CanSino）的新冠肺炎疫苗物流和分销商，该款名为“克威莎”（Convidecia）的疫苗将被配送至各个接种中心。方案集团子公司Solution Biologics私人有限公司是康希诺在东盟的独家经销商和生产合作伙伴，也打算与利直南合作，向私人领域供应克威莎疫苗

发布于 2021年09月01日 15时46分 • 最后更新 2小时前 • 报导：雷洁敏
方案集团携手利直南　助政府加速新冠疫苗接种率

（吉隆坡1日讯）方案集团（SOLUTN，0093，创业板）和利直南（DKSH，5908，主板消费股）携手合作，协助政府加速新冠肺炎疫苗接种率，尽快把疫苗配送到卫生部营运的各个接种中心，并确保以安全可靠的方式处理疫苗。

方案集团周三发文告指出，利直南已被卫生部指定为处理中国康希诺公司（CanSino）的新冠肺炎疫苗物流和分销商，该款名为“克威莎”（Convidecia）的疫苗将被配送至各个接种中心。方案集团子公司Solution Biologics私人有限公司是康希诺在东盟的独家经销商和生产合作伙伴，也打算与利直南合作，向私人领域供应克威莎疫苗

发布于 2021年09月01日 15时46分 • 最后更新 2小时前 • 报导：雷洁敏
方案集团携手利直南　助政府加速新冠疫苗接种率

（吉隆坡1日讯）方案集团（SOLUTN，0093，创业板）和利直南（DKSH，5908，主板消费股）携手合作，协助政府加速新冠肺炎疫苗接种率，尽快把疫苗配送到卫生部营运的各个接种中心，并确保以安全可靠的方式处理疫苗。

方案集团周三发文告指出，利直南已被卫生部指定为处理中国康希诺公司（CanSino）的新冠肺炎疫苗物流和分销商，该款名为“克威莎”（Convidecia）的疫苗将被配送至各个接种中心。方案集团子公司Solution Biologics私人有限公司是康希诺在东盟的独家经销商和生产合作伙伴，也打算与利直南合作，向私人领域供应克威莎疫苗

发布于 2021年09月01日 15时46分 • 最后更新 2小时前 • 报导：雷洁敏
方案集团携手利直南　助政府加速新冠疫苗接种率

（吉隆坡1日讯）方案集团（SOLUTN，0093，创业板）和利直南（DKSH，5908，主板消费股）携手合作，协助政府加速新冠肺炎疫苗接种率，尽快把疫苗配送到卫生部营运的各个接种中心，并确保以安全可靠的方式处理疫苗。

方案集团周三发文告指出，利直南已被卫生部指定为处理中国康希诺公司（CanSino）的新冠肺炎疫苗物流和分销商，该款名为“克威莎”（Convidecia）的疫苗将被配送至各个接种中心。方案集团子公司Solution Biologics私人有限公司是康希诺在东盟的独家经销商和生产合作伙伴，也打算与利直南合作，向私人领域供应克威莎疫苗

发布于 2021年09月01日 15时46分 • 最后更新 2小时前 • 报导：雷洁敏
方案集团携手利直南　助政府加速新冠疫苗接种率

（吉隆坡1日讯）方案集团（SOLUTN，0093，创业板）和利直南（DKSH，5908，主板消费股）携手合作，协助政府加速新冠肺炎疫苗接种率，尽快把疫苗配送到卫生部营运的各个接种中心，并确保以安全可靠的方式处理疫苗。

方案集团周三发文告指出，利直南已被卫生部指定为处理中国康希诺公司（CanSino）的新冠肺炎疫苗物流和分销商，该款名为“克威莎”（Convidecia）的疫苗将被配送至各个接种中心。方案集团子公司Solution Biologics私人有限公司是康希诺在东盟的独家经销商和生产合作伙伴，也打算与利直南合作，向私人领域供应克威莎疫苗

发布于 2021年09月01日 15时46分 • 最后更新 2小时前 • 报导：雷洁敏
方案集团携手利直南　助政府加速新冠疫苗接种率

（吉隆坡1日讯）方案集团（SOLUTN，0093，创业板）和利直南（DKSH，5908，主板消费股）携手合作，协助政府加速新冠肺炎疫苗接种率，尽快把疫苗配送到卫生部营运的各个接种中心，并确保以安全可靠的方式处理疫苗。

方案集团周三发文告指出，利直南已被卫生部指定为处理中国康希诺公司（CanSino）的新冠肺炎疫苗物流和分销商，该款名为“克威莎”（Convidecia）的疫苗将被配送至各个接种中心。方案集团子公司Solution Biologics私人有限公司是康希诺在东盟的独家经销商和生产合作伙伴，也打算与利直南合作，向私人领域供应克威莎疫苗

发布于 2021年09月01日 15时46分 • 最后更新 2小时前 • 报导：雷洁敏
方案集团携手利直南　助政府加速新冠疫苗接种率

（吉隆坡1日讯）方案集团（SOLUTN，0093，创业板）和利直南（DKSH，5908，主板消费股）携手合作，协助政府加速新冠肺炎疫苗接种率，尽快把疫苗配送到卫生部营运的各个接种中心，并确保以安全可靠的方式处理疫苗。

方案集团周三发文告指出，利直南已被卫生部指定为处理中国康希诺公司（CanSino）的新冠肺炎疫苗物流和分销商，该款名为“克威莎”（Convidecia）的疫苗将被配送至各个接种中心。方案集团子公司Solution Biologics私人有限公司是康希诺在东盟的独家经销商和生产合作伙伴，也打算与利直南合作，向私人领域供应克威莎疫苗

财经
发布于 2021年09月01日 15时46分 • 最后更新 2小时前 • 报导：雷洁敏
方案集团携手利直南　助政府加速新冠疫苗接种率

（吉隆坡1日讯）方案集团（SOLUTN，0093，创业板）和利直南（DKSH，5908，主板消费股）携手合作，协助政府加速新冠肺炎疫苗接种率，尽快把疫苗配送到卫生部营运的各个接种中心，并确保以安全可靠的方式处理疫苗。

方案集团周三发文告指出，利直南已被卫生部指定为处理中国康希诺公司（CanSino）的新冠肺炎疫苗物流和分销商，该款名为“克威莎”（Convidecia）的疫苗将被配送至各个接种中心。方案集团子公司Solution Biologics私人有限公司是康希诺在东盟的独家经销商和生产合作伙伴，也打算与利直南合作，向私人领域供应克威莎疫苗

https://www.orientaldaily.com.my/news/business/2021/09/01/435015

buy more

NTA RM2.99 now

yes Trum @undervalued

hold QES tight

The Group kicked off the second half of the financial year positively, contributed by strong order from its medical segments.

The Group was affected by FMCO (MCO 3.0) due to the limiting of workforce to 60% from June to August. There was also a Covid-19 case detected in the factory which resulted in closure of the plants for 7 days in July 2021, which further affected production. With fully vaccination of
employees on 26th August 2021, the Group will be applying to authority for approval of 80~100% workforce capacity.

Next QR sure break through !!!!!!! Cheers !!!

https://www.facebook.com/12invest.my/videos/414479280097442/

MYEG

MYEG

https://www.facebook.com/12invest.my/videos/414479280097442/

Very Good video

GG

good QR

Tomorrow fly over RM1

Accumulating more

Tomorrow sure over RM1.00

即时财经/ 金属硅厂贡献增 齐力科技次季多赚7.48倍 - https://www.sinchew.com.my/content/content_2535189.html (Share from StockHunter)

theedgemarkets.com

August 23, 2021 19:13 pm

PMB Technology 2Q net profit soars more than eight-fold y-o-y, lifted by better contributions across business segments

KUALA LUMPUR (Aug 23): PMB Technology Bhd saw its net profit soar more than eight times to RM11.58 million in the second quarter ended June 30, 2021 (2QFY21) from RM1.37 million a year ago, aided by improved contributions by its manufacturing & trading and construction & fabrication segments.

Earnings per share ballooned to 5.62 sen in 2QFY21, compared with 0.67 sen in 2QFY20, said the aluminium manufacturer and distributor in a filing with Bursa Malaysia.

Revenue for the quarter also swelled more than two times to RM178.25 million year-on-year (y-o-y) from RM84.87 million.

The revenue from the manufacturing & trading segment increased by 179% to RM119.5 million versus RM42.8 million a year ago, mainly due to higher sales from the metallic silicon plant during the current quarter under review.

Meanwhile, revenue from the construction & fabrication segment increased by 40% to RM58.7 million compared with RM42 million a year before, largely because the progress of certain ongoing projects was sped up.

The stellar results lifted PMB Technology's cumulative net profit for the six-month period ended June 30, 2021 (1HFY21) up 396.35% to RM18.21 million from RM3.67 million in 1HFY20. Cumulative revenue also increased by 30.55% to RM340.08 million for 1HFY21 compared with RM260.49 million a year earlier.

On prospects, the group warned that its operating costs have increased, despite having benefitted from the upward trend of metallic silicon prices. Hence, it will continue to focus on production efficiency and to undertake appropriate austerity measures.

Shares of PMB Technology closed up five sen or 0.88% at RM5.70, giving it a market capitalisation of RM1.22 billion. Over the past one year, the stock has rallied 127% from RM2.51.

We wish TP after ex is RM1.20.

Congratulations all shareholders, very good QR

congrats

Source: Kenanga Research - 23 Jun 2021

Source: Kenanga Research - 23 Jun 2021

Supercomnet Technologies Bhd (Trading Buy)

SCOMNET is in the business of manufacturing and assembling advanced high technology wires and cables for the medicaldevices, electrical appliances, consumer electronics and automotive markets.

The group, which announced net profit of RM23.5m (+21% YoY) in FY December 2020, has seen its bottomline increasingevery year since FY17, translating to a robust 3-year CAGR of 115.3%.

With the earnings growth momentum extending into 1QFY21 – as net profit jumped 19% YoY to RM4.9m – consensus isprojecting SCOMNET to make net earnings of RM30.0m for FY21 and RM48.0m for FY22. This implies forward PERs of40.2x this year and 25.1x next year, respectively.

Financially steady, the group has zero borrowings with a cash surplus of RM51.8m (or 7.2 sen per share) as of end-March2021.

On the chart, following a share price correction from a high of RM2.08 in late April this year, the stock has subsequentlybounced off the 38.2% Fibonacci retracement level to pave the way for the shares to shift higher ahead.

With the RSI indicator already emerging from an oversold position and the MACD line crossing over the signal line in anoversold area, a technical rebound is anticipated.

Riding on the positive momentum, the stock will probably climb towards our resistance thresholds of RM1.89 (R1; 13% upsidepotential) and RM2.05 (R2; 23% upside potential).

Our stop loss price is set at RM1.48 (representing a 11% downside risk)

Solution Group Bhd (Trading Buy)

A vaccine play, SOLUTN is set to supply 3.5m doses of Covid-19 vaccine starting from July this year under an agreementpreviously signed with the government, as Malaysia plans to accelerate the vaccination programme to bring the Covid-19pandemic under control as quickly as possible.

This follows last Thursday’s conditional approval given by the Drug Control Authority for the product registration of the singledose Convidecia Covid-19 vaccine produced by China’s CanSino Biologics, which has earlier authorised and granted theexclusive right to SOLUTN to register, manufacture (by providing fill-and-finish services) and commercialise the vaccine in Malaysia.

Via the collaboration, CanSino will also be using SOLUTN’s fill-and-finish facility as the regional hub to market and distributethe COVID-19 vaccine in the ASEAN countries except Indonesia.

The venture marks the group’s diversification into the bio-pharmaceutical related business, complementing its existingbusiness segments, namely engineering equipment, industrial automation, biotechnology, industrial lubricants, metalfabrication & assembly and solar energy.

The group – which posted a marginal net loss of RM1.7m in 1QFY21 – is in a financially healthy position with net cashholdings & short-term investments of RM39.5m (or 9.3 sen per share) as of end-March 2021.

Technically speaking, after bouncing off an ascending trendline and the 50% Fibonacci retracement level on numerousoccasions since November last year, the share price uptrend remains intact.

With the stochastics indicator about to climb out from an oversold area, the stock is expected to advance towards ourresistance thresholds of RM1.36 (R1; 15% upside potential) and RM1.48 (R2; 25% upside potential).

We have pegged our stop loss price at RM1.03 (or 13% downside risk from yesterday’s close of RM1.18).

done top up

will fly over RM2.00

Solution Group Hands Over 200,000 Finished Doses Of Convidecia Vaccine To MOH
By BusinessToday -August 20, 2021

this year double digits growth is not an issue & because the manufacturing biz is catching up.
will accumulating more.

Congratulations to all buddies

a lot of new projects is coming in

The Board of Directors of Willowglen MSC Berhad (“the Company”) is pleased to announce that the Company’s wholly-owned subsidiary, Willowglen Services Pte Ltd has been awarded the following contracts on 16 August 2021:



1) A contract valued equivalent to approximately RM16,700,000 by China Communications Construction Company Limited (Singapore Branch) for the Design, Supply, Install, Testing and Commissioning of Security System for Proposed Development of Intra Airside Road Connection, Second Parallel Taxiway and Fire Station No. 2 for Changi East at Singapore Changi Airport.



The commencement date of the contract is on 24 August 2021 and will be completed by 17 September 2024. The contract is expected to contribute positively to the Group’s earnings and net assets per share for the financial years ending 31 December 2021 to 2024.



2) A term contract valued equivalent to approximately RM7,660,000 by SP PowerAssets Limited, Singapore for the Supply and Delivery of Sub-station Intrusion Detection System (SSIDS) Devices and Removal and Disposal Works.



The commencement date of the contract is on 16 August 2021 and will be completed by 15 August 2026. The contract is expected to contribute positively to the Group’s earnings and net assets per share for the financial years ending 31 December 2021 to 2026.